Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.55 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.55 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.55 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.55 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | TACR2 | P21452 | 1/20 | 0.55 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.55 |
| ▸ | HTR2B | P41595 | 1/20 | 0.55 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6444507 | 1.00 | CYP3A4 (0.55) | CYP3A4OPRM1OPRK1ABCC3ABCC4 | |
| SCHEMBL8861474 | 0.89 | CYP3A4 (0.56) | CYP3A4OPRM1OPRK1ABCC3ABCC4 | |
| SCHEMBL5344398 | 0.87 | CYP3A4 (0.58) | CYP3A4OPRM1OPRK1ABCC3ABCC4 | |
| SCHEMBL6429132 | 0.87 | CYP3A4 (0.58) | CYP3A4OPRM1OPRK1ABCC3ABCC4 | |
| SCHEMBL6443044 | 0.87 | CYP3A4 (0.58) | CYP3A4OPRM1OPRK1ABCC3ABCC4 | |
| SCHEMBL6443042 | 0.87 | CYP3A4 (0.58) | CYP3A4OPRM1OPRK1ABCC3ABCC4 | |
| SCHEMBL27417156 | 0.87 | CYP3A4 (0.58) | CYP3A4OPRM1OPRK1ABCC3ABCC4 | |
| SCHEMBL8562300 | 0.86 | CYP3A4 (0.62) | CYP3A4OPRM1OPRK1ABCC3ABCC4 | |
| SCHEMBL6225032 | 0.86 | CYP3A4 (0.62) | CYP3A4OPRM1OPRK1ABCC3ABCC4 | |
| SCHEMBL8568365 | 0.85 | CYP3A4 (0.56) | CYP3A4OPRM1OPRK1ABCC3ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| EP-0604368-B1 | Anti retroviral hydrazine derivatives | CIBA GEIGY AG (CH) | 1996-09-18 | — | — | EP | disclosed |
| EP-0604368-A1 | Anti retroviral hydrazine derivatives | CIBA-GEIGY AG (CH) | 1994-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | CYP3A4 2875/4885OPRM1 3906/4885OPRK1 3238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.